Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later

Katja Hoschler; Nick J. Andrews; Saul N. Faust; Adam Finn; Andrew J. Pollard; Matthew D. Snape; Woolf T. Walker; Maria Zambon; Elizabeth Miller

doi:10.1093/cid/cit692

Administration of AS03_B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later

Katja Hoschler^*, Nick J. Andrews, Saul N. Faust, Adam Finn, Andrew J. Pollard, Matthew D. Snape, Woolf T. Walker, Maria Zambon, Elizabeth Miller

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Background. We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03_B-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV.Methods. Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays. In children aged <3 years, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared with nonadjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In children aged >3 years, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken before and after the pandemic vaccine were also analyzed by HAI using A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03_B-adjuvanted vaccine but only 1.4% in the nonadjuvanted group had a 4-fold rise to A/Perth/16/2009.Conclusion. AS03_B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in children aged <3 years 1 year later.

Original language	English
Pages (from-to)	181-187
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	58
Issue number	2
DOIs	https://doi.org/10.1093/cid/cit692
Publication status	Published - 15 Jan 2014

Bibliographical note

Funding Information:
Potential conflicts of interest. M. Z. and K. H. have been investigators of clinical trials sponsored by Novartis, Baxter, Sanofi Pasteur, and CSL Australia Ltd. A. J. P. acts as chief investigator for clinical trials on behalf of Oxford University; these trials are funded by vaccine manufacturers, and his institution receives unrestricted educational grants for conferences and seminars. A. J. P. does not receive any personal payments from industry. A. F. and S. N. F. undertake research, consultancy, and educational work for Sanofi Pasteur MSD (SPMSD), Novartis, GSK, Takeda, and Pfizer and for GSK, Pfizer, SPMSD, and Novartis, respectively. In 2006, K. H. has received financial assistance from SPMSD to attend a conference. S. N. F. has received financial assistance from GSK, Pfizer, and SPMSD to attend conferences. All grants and honoraria are paid into accounts of the respective employers (eg, NHS trusts, universities, health protection agencies) or to independent charities and none received personally. All other authors report no potential conflicts. All other authors have no conflicts of interest.

Funding Information:
Financial support. The fieldwork was funded by the NIHR Health Technology Assessment program and the laboratory testing and analysis by the Health Protection Agency.

Keywords

Childhood
Cross-reactive effects
Influenza
Oil-in-water adjuvant
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/cit692

Cite this

Hoschler, K., Andrews, N. J., Faust, S. N., Finn, A., Pollard, A. J., Snape, M. D., Walker, W. T., Zambon, M., & Miller, E. (2014). Administration of AS03_B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. Clinical Infectious Diseases, 58(2), 181-187. https://doi.org/10.1093/cid/cit692

@article{8d486edfbb224ab695ffcf5f11ac793d,

title = "Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later",

abstract = "Background. We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03B-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV.Methods. Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays. In children aged <3 years, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared with nonadjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In children aged >3 years, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken before and after the pandemic vaccine were also analyzed by HAI using A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03B-adjuvanted vaccine but only 1.4% in the nonadjuvanted group had a 4-fold rise to A/Perth/16/2009.Conclusion. AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in children aged <3 years 1 year later.",

keywords = "Childhood, Cross-reactive effects, Influenza, Oil-in-water adjuvant, Vaccine",

author = "Katja Hoschler and Andrews, {Nick J.} and Faust, {Saul N.} and Adam Finn and Pollard, {Andrew J.} and Snape, {Matthew D.} and Walker, {Woolf T.} and Maria Zambon and Elizabeth Miller",

note = "Funding Information: Potential conflicts of interest. M. Z. and K. H. have been investigators of clinical trials sponsored by Novartis, Baxter, Sanofi Pasteur, and CSL Australia Ltd. A. J. P. acts as chief investigator for clinical trials on behalf of Oxford University; these trials are funded by vaccine manufacturers, and his institution receives unrestricted educational grants for conferences and seminars. A. J. P. does not receive any personal payments from industry. A. F. and S. N. F. undertake research, consultancy, and educational work for Sanofi Pasteur MSD (SPMSD), Novartis, GSK, Takeda, and Pfizer and for GSK, Pfizer, SPMSD, and Novartis, respectively. In 2006, K. H. has received financial assistance from SPMSD to attend a conference. S. N. F. has received financial assistance from GSK, Pfizer, and SPMSD to attend conferences. All grants and honoraria are paid into accounts of the respective employers (eg, NHS trusts, universities, health protection agencies) or to independent charities and none received personally. All other authors report no potential conflicts. All other authors have no conflicts of interest. Funding Information: Financial support. The fieldwork was funded by the NIHR Health Technology Assessment program and the laboratory testing and analysis by the Health Protection Agency.",

year = "2014",

month = jan,

day = "15",

doi = "10.1093/cid/cit692",

language = "English",

volume = "58",

pages = "181--187",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "2",

}

Hoschler, K , Andrews, NJ, Faust, SN, Finn, A, Pollard, AJ, Snape, MD, Walker, WT, Zambon, M & Miller, E 2014, 'Administration of AS03_B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later', Clinical Infectious Diseases, vol. 58, no. 2, pp. 181-187. https://doi.org/10.1093/cid/cit692

Administration of AS03_B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later. / Hoschler, Katja ; Andrews, Nick J.; Faust, Saul N. et al.
In: Clinical Infectious Diseases, Vol. 58, No. 2, 15.01.2014, p. 181-187.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later

AU - Hoschler, Katja

AU - Andrews, Nick J.

AU - Faust, Saul N.

AU - Finn, Adam

AU - Pollard, Andrew J.

AU - Snape, Matthew D.

AU - Walker, Woolf T.

AU - Zambon, Maria

AU - Miller, Elizabeth

N1 - Funding Information: Potential conflicts of interest. M. Z. and K. H. have been investigators of clinical trials sponsored by Novartis, Baxter, Sanofi Pasteur, and CSL Australia Ltd. A. J. P. acts as chief investigator for clinical trials on behalf of Oxford University; these trials are funded by vaccine manufacturers, and his institution receives unrestricted educational grants for conferences and seminars. A. J. P. does not receive any personal payments from industry. A. F. and S. N. F. undertake research, consultancy, and educational work for Sanofi Pasteur MSD (SPMSD), Novartis, GSK, Takeda, and Pfizer and for GSK, Pfizer, SPMSD, and Novartis, respectively. In 2006, K. H. has received financial assistance from SPMSD to attend a conference. S. N. F. has received financial assistance from GSK, Pfizer, and SPMSD to attend conferences. All grants and honoraria are paid into accounts of the respective employers (eg, NHS trusts, universities, health protection agencies) or to independent charities and none received personally. All other authors report no potential conflicts. All other authors have no conflicts of interest. Funding Information: Financial support. The fieldwork was funded by the NIHR Health Technology Assessment program and the laboratory testing and analysis by the Health Protection Agency.

PY - 2014/1/15

Y1 - 2014/1/15

N2 - Background. We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03B-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV.Methods. Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays. In children aged <3 years, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared with nonadjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In children aged >3 years, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken before and after the pandemic vaccine were also analyzed by HAI using A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03B-adjuvanted vaccine but only 1.4% in the nonadjuvanted group had a 4-fold rise to A/Perth/16/2009.Conclusion. AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in children aged <3 years 1 year later.

AB - Background. We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03B-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody responses to the H3N2 A/Perth/16/2009 and B/Brisbane/60/2008 components of TIV.Methods. Vaccine responses were analyzed using hemagglutination inhibition (HAI) assays. In children aged <3 years, previous receipt of adjuvanted vaccine resulted in higher HAI antibody responses to H3N2 and B strains compared with nonadjuvanted vaccine (fold change 16.8 vs 4.3 for H3N2 and 7.0 vs 1.6 for B). In children aged >3 years, responses to the H3 and B components of TIV were similar between vaccine groups. Sera taken before and after the pandemic vaccine were also analyzed by HAI using A/Perth/16/2009 virus. This analysis showed that 11.1% of children receiving the AS03B-adjuvanted vaccine but only 1.4% in the nonadjuvanted group had a 4-fold rise to A/Perth/16/2009.Conclusion. AS03B-adjuvanted A(H1N1)pdm09 influenza vaccine generates a cross-reactive antibody response to H3N2 in children and enhances responses to heterologous subtypes in children aged <3 years 1 year later.

KW - Childhood

KW - Cross-reactive effects

KW - Influenza

KW - Oil-in-water adjuvant

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84891806093&partnerID=8YFLogxK

U2 - 10.1093/cid/cit692

DO - 10.1093/cid/cit692

M3 - Article

C2 - 24149079

AN - SCOPUS:84891806093

SN - 1058-4838

VL - 58

SP - 181

EP - 187

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 2

ER -